Aeglea BioTherapeutics Inc

NASDAQ:AGLE 3:59:59 PM EDT

7.09

-0.15 (-2.07%)

Market Cap (Intraday)	347.56M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$13 Million
Adjusted EPS	-$0.19

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE

805 Las Cimas Parkway, Suite 100, Austin, Texas 78746

United States of America

Phone: +1.512.942.2935

Number of Employees: 90

http://www.aegleabio.com

Description

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.